soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 reduced the risk of clinically important kidney and death from (CV) causes in patients with type 2 diabetes (T2D) and CKD ca. #ERA24 🇸🇪 #Nephpearls https://www.nejm .org/doi/full/10.1056/NEJMoa2403347 Oral Semaglutide and Cardiovascular Outcomes

GLP-1 medications are usually given as injections under the skin, either once a day or once a week, depending on the specific medicine

(2015) GLP-1/glucagon co-agonist REE data, which remains the mechanistic anchor for every triagonist programme that followed [unverified]

Less than half do it in a way that protects their physiology

Ask a close friend, companion, spouse, or relative to learn how to administer vitamin B12 shots, or at least hold a mirror for you while you give yourself the injection, and rub out the pain afterwards to prevent bruising and other painful side effects

Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists